No evidence for substrate accumulation in Parkinson brains with GBA mutations

Movement Disorders

Volumn 30, Issue 8, 2015, Pages 1085-1089

  Gegg, Matthew E ^a   Sweet, Lindsay ^b   Wang, Bing H ^b   Shihabuddin, Lamya S ^b   Sardi, Sergio Pablo ^b   Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SANOFI   (France)

Author keywords

glucocerebrosidase; lysosomes; Parkinson's disease; sphingolipids

Indexed keywords

GANGLIOSIDE GM2; GANGLIOSIDE GM3; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; SPHINGOMYELIN; BETA GLUCOSIDASE;

ARTICLE; CEREBELLUM; CHOLESTEROL BLOOD LEVEL; ENZYME SUBSTRATE; GBA1 GENE; GENE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MUTATION ACCUMULATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROCEDURES; PUTAMEN; GENETICS; METABOLISM; MUTATION; PATHOLOGY; TISSUE BANK;

BETA-GLUCOSIDASE; CEREBELLUM; GLUCOSYLCERAMIDASE; HUMANS; MUTATION; PUTAMEN; TISSUE BANKS;

EID: 84931412885     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26278     Document Type: Article

References (29)

1. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651–1661.
2. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009;132:1783–1794.
3. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008;372:1263–1271.
4. Gegg ME, Burke D, Heales SJR, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012;72:455–463.
5. Murphy KE, Gysbers AM, Abbott SK, et al. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain 2014;137:834–848.
6. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol 2010;67:1464–1472.
7. Dehay B, Bové J, Rodríguez-Muela N, et al. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 2010;30:12535–12544.
8. Gegg ME, Schapira AH V. PINK1-parkin-dependent mitophagy involves ubiquitination of mitofusins 1 and 2: Implications for Parkinson disease pathogenesis. Autophagy 2011;7:243–245.
9. Mazzulli JR, Xu Y-H, Sun Y, et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:37–52.
10. Sardi SP, Clarke J, Kinnecom C, et al. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci U S A 2011;108:12101–12106.
11. Osellame LD, Rahim AA, Hargreaves IP, et al. Mitochondria and quality control defects in a mouse model of Gaucher disease: links to Parkinson's disease. Cell Metab 2013;17:941–953.
12. Cullen V, Sardi SP, Ng J, et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol 2011;69:940–953.
13. Schöndorf DC, Aureli M, McAllister FE, et al. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun 2014;5:4028–4045.
14. Sun Y, Zhang W, Xu Y-H, et al. Substrate compositional variation with tissue/region and Gba1 mutations in mouse models: implications for Gaucher disease. PLoS One 2013;8:e57560.
15. Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem 1982;39:709–718.
16. Nilsson O, Grabowski GA, Ludman MD, Desnick RJ, Svennerholm L. Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants. Clin Genet 1985;27:443–450.
17. Orvisky E, Park JK, LaMarca ME, et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab 2002;76:262–270.
18. Abbott SK, Li H, Muñoz SS, et al. Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. Mov Disord 2014;29:518–526.
19. Duran R, Mencacci NE, Angeli AV, et al. The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Mov Disord 2013;28:232–236.
20. Grace ME, Ashton-Prolla P, Pastores GM, Soni A, Desnick RJ. Non-pseudogene-derived complex acid beta-glucosidase mutations causing mild type 1 and severe type 2 gaucher disease. J Clin Invest 1999;103:817–823.
21. Montfort M, Chabás A, Vilageliu L, Grinberg D. Functional analysis of 13 GBA mutant alleles identified in Gaucher disease patients: pathogenic changes and “modifier” polymorphisms. Hum Mutat 2004;23:567–575.
22. Liou B, Grabowski GA. Is E326K glucocerebrosidase a polymorphic or pathological variant? Mol Genet Metab 2012;105:528–529.
23. McNeill A, Magalhaes J, Shen C, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 2014;137:1481–1495.
24. Lamb CA, Yoshimori T, Tooze SA. The autophagosome: origins unknown, biogenesis complex. Nat Rev Mol Cell Biol 2013;14:759–774.
25. Koga H, Kaushik S, Cuervo AM. Altered lipid content inhibits autophagic vesicular fusion. FASEB J 2010;24:3052–3065.
26. Kaushik S, Massey AC, Cuervo AM. Lysosome membrane lipid microdomains: novel regulators of chaperone-mediated autophagy. EMBO J 2006;25:3921–3933.
27. Rodriguez-Navarro JA, Kaushik S, Koga H, et al. Inhibitory effect of dietary lipids on chaperone-mediated autophagy. Proc Natl Acad Sci U S A 2012;109:e705–E714.
28. Fabelo N, Martín V, Santpere G, et al. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol Med 2011;17:1107–1118.
29. Brockmann K, Hilker R, Pilatus U, et al. GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology 2012;79:213–220.